Stockscreener 앱 받기
21.40
0.44%
-0.01
전일 마감가:
$21.41
열려 있는:
$21.01
하루 거래량:
127.62K
Relative Volume:
0.07
시가총액:
$1.72B
수익:
$203.45M
순이익/손실:
$-351.45M
주가수익비율:
-4.7033
EPS:
-4.55
순현금흐름:
$-369.41M
1주 성능:
+6.15%
1개월 성능:
+42.19%
6개월 성능:
+23.21%
1년 성능:
+225.42%
1일 변동 폭
$20.83
$21.41
1주일 범위
$19.69
$22.07
52주 변동 폭
$6.01
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
명칭
Travere Therapeutics Inc
전화
888-969-7879
주소
3611 VALLEY CENTRE DR, SAN DIEGO
TVTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
21.38 | 1.72B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.03 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
579.75 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
644.79 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.79 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
252.33 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-21 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-09 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-12-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-20 | 개시 | Citigroup | Neutral |
| 2023-09-22 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 재개 | Evercore ISI | Outperform |
| 2023-07-21 | 개시 | JP Morgan | Overweight |
| 2023-06-07 | 재개 | Piper Sandler | Neutral |
| 2023-05-22 | 개시 | TD Cowen | Outperform |
| 2023-05-05 | 업그레이드 | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-21 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-12-14 | 개시 | Stifel | Hold |
| 2022-12-05 | 개시 | Wells Fargo | Overweight |
| 2022-09-21 | 개시 | Bryan Garnier | Sell |
| 2022-07-14 | 재개 | Canaccord Genuity | Buy |
| 2022-03-31 | 개시 | Piper Sandler | Overweight |
| 2022-02-28 | 개시 | H.C. Wainwright | Buy |
| 2021-05-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
모두보기
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Homocystinuria Market Growth, Trends & Forecast 2025 | Leading - openPR.com
Travere therapeutics CEO sells $398k in stock By Investing.com - Investing.com Nigeria
Travere therapeutics CEO sells $398k in stock - Investing.com Australia
Travere therapeutics CFO sells shares worth $37,553 - Investing.com Australia
Travere Therapeutics Executives Sell Shares - TradingView
Travere Therapeutics anticipates FILSPARI approval for FSGS by September 2025 - MSN
(TVTX) Technical Data - news.stocktradersdaily.com
Analysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter Report - Yahoo Finance
Travere Therapeutics (TVTX) Sees Promising Growth with FILSPARI - GuruFocus
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Travere Therapeutics Inc (TVTX): A Strategic SWOT Insig - GuruFocus
Travere Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Travere Therapeutics (TVTX) Rating and Price Target Update by We - GuruFocus
Travere Therapeutics (TVTX) Price Target Raised by Stifel | TVTX Stock News - GuruFocus
Travere Therapeutics Inc (TVTX) Q1 2025 Earnings Call Highlights: Robust Sales Growth Amidst ... - Yahoo
Travere: Q1 Earnings Snapshot - Norwalk Hour
Travere Therapeutics Reports Strong Q1 2025 Financial Results - TipRanks
Travere Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Travere Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:TVTX) - Seeking Alpha
Earnings call transcript: Travere Therapeutics beats Q1 2025 EPS forecast By Investing.com - Investing.com South Africa
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Travere Therapeutics Reports First Quarter 2025 Financial Results - BioSpace
Earnings call transcript: Travere Therapeutics beats Q1 2025 EPS forecast - Investing.com
Travere Therapeutics (TVTX) Surpasses Revenue Expectations in Q1 - GuruFocus
Travere Therapeutics (TVTX) Surpasses Revenue Expectations in Q1 | TVTX Stock News - GuruFocus
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (TVTX) Travere Therapeutics Q1 Adjusted Loss Per Share $0.19 vs. FactSet Est Loss $0.36 - marketscreener.com
Travere Therapeutics, Inc. SEC 10-Q Report - TradingView
Travere, CSL gets standard EU approval for kidney disorder treatment - MSN
Travere Therapeutics (TVTX) Gains Standard EU Approval for Filsp - GuruFocus
European Commission Grants Standard Approval for Travere's Filsp - GuruFocus
Travere, CSL get standard EU nod for kidney drug (TVTX:NASDAQ) - Seeking Alpha
Travere, CSL Vifor Receive EU Marketing Approval for Filspari in IgA Nephropathy - marketscreener.com
Travere Therapeutics and CSL Vifor Announce Standard EU Approval - GuruFocus
How to interpret Travere Therapeutics Inc (TVTX)’s stock chart patterns - uspostnews.com
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy | TVTX Stock News - GuruFocus
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy - Business Wire
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy - The Manila Times
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy | CSLLY Stock News - GuruFocus
Breakthrough: FILSPARI Secures Standard EU Approval as First DEARA Therapy for IgA Nephropathy - Stock Titan
Cantor Fitzgerald maintains overweight on Travere Therapeutics stock By Investing.com - Investing.com Canada
Travere Therapeutics (TVTX) – Research Analysts’ Recent Ratings Updates - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Travere Therapeutics Inc [NASDAQ: TVTX] Sees Increase in Stock Value - knoxdaily.com
Cantor Fitzgerald Reaffirms “Overweight” Rating for Travere Therapeutics (NASDAQ:TVTX) - Defense World
Travere Therapeutics to Report First Quarter 2025 Financial Resu - GuruFocus
Travere Therapeutics to Report First Quarter 2025 Financial Results - Business Wire
Assessing Travere Therapeutics: Insights From 8 Financial Analysts - Benzinga
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Cantor Fitzgerald maintains Overweight on Travere Therapeutics stock By Investing.com - Investing.com Canada
Commit To Purchase Travere Therapeutics At $15, Earn 22.8% Annualized Using Options - Nasdaq
Travere Therapeutics Inc (TVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.71%
자본화:
|
볼륨(24시간):